Key result
Non-alcoholic fatty liver disease promotes atherosclerosis through systemic dyslipidemia, inflammation, oxidative stress, hepatokine production, and coagulation.
Why the study?
Cardiovascular disease and atherosclerosis are common complications and major causes of death in patients with NAFLD, but the mechanisms linking NAFLD-induced metabolic burden to atherosclerosis require clarification.
NAFLD is a significant metabolic burden that promotes atherosclerosis, suggesting that managing NAFLD may be a viable therapeutic strategy for reducing cardiovascular disease risk.
CVD risk assessment essential in NAFLD; leaves open whether liver-directed therapies reduce atherosclerotic events.
Non-alcoholic fatty liver disease (NAFLD) has become the fastest growing chronic liver disease, with a prevalence of up to 25% worldwide. Individuals with NAFLD have a high risk of disease progression to cirrhosis, hepatocellular carcinoma (HCC), and liver failure. With the exception of intrahepatic burden, cardiovascular disease (CVD) and especially atherosclerosis (AS) are common complications of NAFLD. Furthermore, CVD is a major cause of death in NAFLD patients. Additionally, AS is a metabolic disorder highly associated with NAFLD, and individual NAFLD pathologies can greatly increase the risk of AS. It is increasingly clear that AS-associated endothelial cell damage, inflammatory cell activation, and smooth muscle cell proliferation are extensively impacted by NAFLD-induced systematic dyslipidemia, inflammation, oxidative stress, the production of hepatokines, and coagulations. In clinical trials, drug candidates for NAFLD management have displayed promising effects for the treatment of AS. In this review, we summarize the key molecular events and cellular factors contributing to the metabolic burden induced by NAFLD on AS, and discuss therapeutic strategies for the improvement of AS in individuals with NAFLD.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2020) conducted a review in Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic fatty liver disease was evaluated. Non-alcoholic fatty liver disease promotes atherosclerosis through systemic dyslipidemia, inflammation, oxidative stress, hepatokine production, and coagulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: